S&P 500   3,980.35 (+0.01%)
DOW   31,580.63 (+0.00%)
QQQ   298.28 (-0.23%)
AAPL   155.01 (-0.61%)
MSFT   257.35 (-0.29%)
META   160.47 (+0.05%)
GOOGL   108.72 (-0.67%)
AMZN   128.42 (-0.82%)
TSLA   285.24 (+0.54%)
NVDA   137.18 (+0.03%)
NIO   17.43 (-0.29%)
BABA   88.94 (-1.83%)
AMD   81.48 (+2.35%)
T   16.84 (-0.18%)
MU   54.46 (-0.98%)
CGC   3.41 (+0.00%)
F   15.17 (-1.69%)
GE   73.19 (-0.53%)
DIS   111.75 (-0.83%)
AMC   8.43 (+0.48%)
PYPL   95.19 (+0.23%)
PFE   46.37 (+0.52%)
NFLX   225.00 (-1.73%)
S&P 500   3,980.35 (+0.01%)
DOW   31,580.63 (+0.00%)
QQQ   298.28 (-0.23%)
AAPL   155.01 (-0.61%)
MSFT   257.35 (-0.29%)
META   160.47 (+0.05%)
GOOGL   108.72 (-0.67%)
AMZN   128.42 (-0.82%)
TSLA   285.24 (+0.54%)
NVDA   137.18 (+0.03%)
NIO   17.43 (-0.29%)
BABA   88.94 (-1.83%)
AMD   81.48 (+2.35%)
T   16.84 (-0.18%)
MU   54.46 (-0.98%)
CGC   3.41 (+0.00%)
F   15.17 (-1.69%)
GE   73.19 (-0.53%)
DIS   111.75 (-0.83%)
AMC   8.43 (+0.48%)
PYPL   95.19 (+0.23%)
PFE   46.37 (+0.52%)
NFLX   225.00 (-1.73%)
S&P 500   3,980.35 (+0.01%)
DOW   31,580.63 (+0.00%)
QQQ   298.28 (-0.23%)
AAPL   155.01 (-0.61%)
MSFT   257.35 (-0.29%)
META   160.47 (+0.05%)
GOOGL   108.72 (-0.67%)
AMZN   128.42 (-0.82%)
TSLA   285.24 (+0.54%)
NVDA   137.18 (+0.03%)
NIO   17.43 (-0.29%)
BABA   88.94 (-1.83%)
AMD   81.48 (+2.35%)
T   16.84 (-0.18%)
MU   54.46 (-0.98%)
CGC   3.41 (+0.00%)
F   15.17 (-1.69%)
GE   73.19 (-0.53%)
DIS   111.75 (-0.83%)
AMC   8.43 (+0.48%)
PYPL   95.19 (+0.23%)
PFE   46.37 (+0.52%)
NFLX   225.00 (-1.73%)
S&P 500   3,980.35 (+0.01%)
DOW   31,580.63 (+0.00%)
QQQ   298.28 (-0.23%)
AAPL   155.01 (-0.61%)
MSFT   257.35 (-0.29%)
META   160.47 (+0.05%)
GOOGL   108.72 (-0.67%)
AMZN   128.42 (-0.82%)
TSLA   285.24 (+0.54%)
NVDA   137.18 (+0.03%)
NIO   17.43 (-0.29%)
BABA   88.94 (-1.83%)
AMD   81.48 (+2.35%)
T   16.84 (-0.18%)
MU   54.46 (-0.98%)
CGC   3.41 (+0.00%)
F   15.17 (-1.69%)
GE   73.19 (-0.53%)
DIS   111.75 (-0.83%)
AMC   8.43 (+0.48%)
PYPL   95.19 (+0.23%)
PFE   46.37 (+0.52%)
NFLX   225.00 (-1.73%)

Pharmaceutical Stocks List

Compare pharmaceutical stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. ABBV, BMY, GSK, MCK, MRK, MRNA, PFE, JNJ, XPH).

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$139.35
+0.5%
$144.46
$105.56
$175.91
$246.38B0.724.11 million shs17,673 shs
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$68.28
-0.7%
$73.23
$53.22
$80.59
$145.79B0.438.42 million shs77,967 shs
GSK plc stock logo
GSK
GSK
$30.87
-2.0%
$38.59
$31.16
$46.97
$62.78B0.619.18 million shs47,145 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$163.23
-0.5%
$170.84
$155.72
$186.69
$429.16B0.617.03 million shs47,242 shs
McKesson Co. stock logo
MCK
McKesson
$367.76
+0.2%
$346.30
$193.89
$375.23
$52.86B0.59895,086 shs1,842 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$86.51
-0.4%
$90.19
$70.89
$95.72
$219.15B0.336.96 million shs46,085 shs
Moderna, Inc. stock logo
MRNA
Moderna
$139.11
+3.1%
$158.85
$115.61
$464.85
$55.33B1.694.25 million shs46,261 shs
Pfizer Inc. stock logo
PFE
Pfizer
$46.24
+0.2%
$49.81
$40.94
$61.71
$259.52B0.717.40 million shs193,008 shs

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+0.81%+3.16%-1.16%-4.62%+27.22%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
+0.16%+2.00%-6.83%-9.50%+5.48%
GSK plc stock logo
GSK
GSK
+0.06%-3.05%-21.88%-26.84%-23.08%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.55%+1.69%-3.60%-5.55%-4.79%
McKesson Co. stock logo
MCK
McKesson
+1.71%-0.01%+5.64%+17.60%+78.58%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.52%+1.77%-1.83%-1.28%+14.33%
Moderna, Inc. stock logo
MRNA
Moderna
+3.71%+1.99%-26.26%+0.64%-69.09%
Pfizer Inc. stock logo
PFE
Pfizer
+0.81%+1.99%-6.94%-10.91%-1.33%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
2.53 of 5 Stars
2.35.04.23.91.31.71.3
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.56 of 5 Stars
1.35.04.24.01.12.52.5
GSK plc stock logo
GSK
GSK
2.03 of 5 Stars
0.03.03.30.02.10.01.9
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.78 of 5 Stars
2.35.04.23.91.62.51.9
McKesson Co. stock logo
MCK
McKesson
2.51 of 5 Stars
2.43.03.33.02.42.51.9
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.66 of 5 Stars
3.33.04.24.21.11.71.3
Moderna, Inc. stock logo
MRNA
Moderna
2.66 of 5 Stars
3.13.00.04.61.33.32.5
Pfizer Inc. stock logo
PFE
Pfizer
2.67 of 5 Stars
2.33.04.24.31.81.72.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.50
Moderate Buy$159.3514.88% Upside
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.50
Moderate Buy$75.579.91% Upside
GSK plc stock logo
GSK
GSK
2.00
Hold$1,700.005,298.54% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.56
Moderate Buy$189.8915.74% Upside
McKesson Co. stock logo
MCK
McKesson
2.83
Moderate Buy$340.15-7.30% Downside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.63
Moderate Buy$97.4412.17% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.18
Hold$227.7568.83% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.50
Moderate Buy$57.3324.29% Upside

Current Analyst Ratings

Latest GLBS, TOPS, PXS, and NM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2022
GSK plc stock logo
GSK
GSK
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
9/7/2022
GSK plc stock logo
GSK
GSK
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetGBX 1,750 ➝ GBX 1,500
9/7/2022
GSK plc stock logo
GSK
GSK
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetGBX 1,860 ➝ GBX 1,550
9/7/2022
Moderna, Inc. stock logo
MRNA
Moderna
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$155.00 ➝ $165.00
9/1/2022
Pfizer Inc. stock logo
PFE
Pfizer
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
9/1/2022
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$59.00
9/1/2022
Pfizer Inc. stock logo
PFE
Pfizer
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
8/26/2022
Pfizer Inc. stock logo
PFE
Pfizer
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
8/26/2022
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$59.00
8/26/2022
Pfizer Inc. stock logo
PFE
Pfizer
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
8/25/2022
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
(Data available from 9/8/2019 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CA, Inc. stock logo
CA
CA
$4.24B4.39$3.24 per share13.73$14.14 per share3.14

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CA, Inc. stock logo
CA
CA
$476M$2.3219.1616.643.8411.19%15.11%7.46%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$5.644.07%+10.37%79.89%50 Years
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$2.163.14%+7.68%71.76%16 Years
GSK plc stock logo
GSK
GSK
$1.534.86%N/A50.66%N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.522.75%+5.78%65.79%61 Years
McKesson Co. stock logo
MCK
McKesson
$2.160.59%+6.83%22.83%16 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.763.18%+9.88%42.27%12 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.603.47%+4.39%31.31%12 Years

Latest Pharmaceutical Stocks Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/26/2022
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Quarterly$0.693.03%9/14/20229/15/202210/7/2022
7/27/2022
GSK plc stock logo
GSK
GSK
Quarterly$0.38303.57%8/18/20228/19/202210/6/2022
7/25/2022
McKesson Co. stock logo
MCK
McKesson
quarterly$0.540.65%8/31/20229/1/202210/3/2022
7/18/2022
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Quarterly$1.132.63%8/22/20228/23/20229/6/2022
6/23/2022
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.403.22%7/28/20226/29/20229/6/2022
6/23/2022
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.413.77%7/14/20227/15/20228/15/2022
6/16/2022
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
quarterly$0.543%6/30/20227/1/20228/1/2022
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
4.15
0.84
0.75
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
1.14
1.44
1.34
GSK plc stock logo
GSK
GSK
0.83
1.43
1.31
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.37
1.42
1.17
McKesson Co. stock logo
MCK
McKesson
N/A
0.96
0.55
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.66
1.39
1.15
Moderna, Inc. stock logo
MRNA
Moderna
0.04
1.99
1.71
Pfizer Inc. stock logo
PFE
Pfizer
0.39
1.42
1.20

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
68.25%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
76.54%
GSK plc stock logo
GSK
GSK
16.86%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
68.59%
McKesson Co. stock logo
MCK
McKesson
86.43%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
73.33%
Moderna, Inc. stock logo
MRNA
Moderna
60.76%
Pfizer Inc. stock logo
PFE
Pfizer
67.9%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.08%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
0.09%
GSK plc stock logo
GSK
GSK
10%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.35%
McKesson Co. stock logo
MCK
McKesson
0.21%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.29%
Moderna, Inc. stock logo
MRNA
Moderna
17.3%
Pfizer Inc. stock logo
PFE
Pfizer
0.05%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
32,2002.14 billion2.13 billionOptionable
GSK plc stock logo
GSK
GSK
90,0962.03 billion1.83 billionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
141,7002.63 billion2.62 billionOptionable
McKesson Co. stock logo
MCK
McKesson
75,000143.73 million143.43 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
68,0002.53 billion2.53 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
2,700397.76 million328.95 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
79,0005.61 billion5.61 billionOptionable

Pharmaceutical Stocks Headlines

SourceHeadline
Pentagon orders another $4.8B worth of Pfizer’s COVID pills - Herald and NewsPentagon orders another $4.8B worth of Pfizer’s COVID pills - Herald and News
heraldandnews.com - September 8 at 7:57 AM
Alarm over risk of mixing up booster and conventional vaccine - Los Angeles TimesAlarm over risk of mixing up booster and conventional vaccine - Los Angeles Times
latimes.com - September 8 at 2:57 AM
Pfizer to Acquire Australian Digital Health Company for $180 Million - The Epoch TimesPfizer to Acquire Australian Digital Health Company for $180 Million - The Epoch Times
theepochtimes.com - September 8 at 2:57 AM
Pfizer Inc. (PFE) Presents at Citis 17th Annual BioPharma Brokers Conference (Transcript) - Seeking AlphaPfizer Inc. (PFE) Presents at Citi's 17th Annual BioPharma Brokers Conference (Transcript) - Seeking Alpha
seekingalpha.com - September 7 at 9:52 PM
Pfizer (PFE) – Pfizer Whale Trades For September 07 - BenzingaPfizer (PFE) – Pfizer Whale Trades For September 07 - Benzinga
benzinga.com - September 7 at 9:52 PM
FDA Grants Breakthrough Therapy Designation to Pfizers Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women - PfizerFDA Grants Breakthrough Therapy Designation to Pfizer's Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women - Pfizer
pfizer.com - September 7 at 11:50 AM
Pfizer donates Paxlovid to group targeting COVID in poorer countries - ReutersPfizer donates Paxlovid to group targeting COVID in poorer countries - Reuters
reuters.com - September 7 at 11:50 AM
FDA Grants Breakthrough Therapy Designation to Pfizers Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women - Business WireFDA Grants Breakthrough Therapy Designation to Pfizer's Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women - Business Wire
businesswire.com - September 7 at 6:50 AM
Booster jabs in GCC remain ‘critical’ to beat ‘unpredictable’ COVID-19: Pfizer chief - Al Arabiya EnglishBooster jabs in GCC remain ‘critical’ to beat ‘unpredictable’ COVID-19: Pfizer chief - Al Arabiya English
english.alarabiya.net - September 7 at 6:50 AM
COVID: Pfizer, Moderna omicron bivalent boosters confuse providers - USA TODAYCOVID: Pfizer, Moderna omicron bivalent boosters confuse providers - USA TODAY
usatoday.com - September 7 at 6:49 AM
SRHD Supports Recommendation of Pfizer & Moderna Bivalent COVID-19 Boosters | SRHD - Spokane Regional HealthSRHD Supports Recommendation of Pfizer & Moderna Bivalent COVID-19 Boosters | SRHD - Spokane Regional Health
srhd.org - September 7 at 1:49 AM
Heritage Global Partners Awarded New Global Vendor Contract With Pfizer - Business WireHeritage Global Partners Awarded New Global Vendor Contract With Pfizer - Business Wire
businesswire.com - September 6 at 3:48 PM
Pfizer declares special interim dividend of Rs 30 per share - Business StandardPfizer declares special interim dividend of Rs 30 per share - Business Standard
business-standard.com - September 6 at 3:48 PM
Pfizers COVID pill Paxlovid has profound effect in seniors, jury still out for younger adults - Medical Marketing and MediaPfizer's COVID pill Paxlovid has profound effect in seniors, jury still out for younger adults - Medical Marketing and Media
mmm-online.com - September 6 at 3:48 PM
Drug Solutions Podcast: How Pfizer Views Partnering and Investing for Emerging Therapies - Pharmaceutical Technology MagazineDrug Solutions Podcast: How Pfizer Views Partnering and Investing for Emerging Therapies - Pharmaceutical Technology Magazine
pharmtech.com - September 6 at 3:48 PM
Claim that 44% of Pfizer Covid-19 vaccine trial pregnancies ended in miscarriage is wrong - Full FactClaim that 44% of Pfizer Covid-19 vaccine trial pregnancies ended in miscarriage is wrong - Full Fact
fullfact.org - September 6 at 3:48 PM
Israeli research: Myocarditis after Pfizer booster remains rare and mild - The Jerusalem PostIsraeli research: Myocarditis after Pfizer booster remains rare and mild - The Jerusalem Post
jpost.com - September 6 at 3:48 PM
Updated Pfizer and Moderna COVID-19 boosters available at Pandemic Operations Center - Communications and Outreach - Communications and Outreach - North Carolina - New Hanover CountyUpdated Pfizer and Moderna COVID-19 boosters available at Pandemic Operations Center - Communications and Outreach - Communications and Outreach - North Carolina - New Hanover County
news.nhcgov.com - September 6 at 3:48 PM
Shifting Covid Vaccine Coverage to Private Payers Is Good for Moderna, PfizerShifting Covid Vaccine Coverage to Private Payers Is Good for Moderna, Pfizer
gurufocus.com - September 6 at 2:47 PM
Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action (Businesswire)Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action (Businesswire)
avanza.se - September 6 at 10:48 AM
Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now?Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now?
sg.news.yahoo.com - September 6 at 10:48 AM
Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate ActionPfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action
finance.yahoo.com - September 6 at 10:48 AM
Pfizer isnt sharing Covid vaccines with researchers for next-gen studies - STATPfizer isn't sharing Covid vaccines with researchers for next-gen studies - STAT
statnews.com - September 6 at 5:47 AM
Pfizer Inc. (NYSE:PFE) Receives Consensus Rating of "Moderate Buy" from BrokeragesPfizer Inc. (NYSE:PFE) Receives Consensus Rating of "Moderate Buy" from Brokerages
marketbeat.com - September 6 at 2:28 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Bristol-Myers Squibb logo

Bristol-Myers Squibb

NYSE:BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
GSK logo

GSK

NYSE:GSK
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
McKesson logo

McKesson

NYSE:MCK
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Merck & Co., Inc. logo

Merck & Co., Inc.

NYSE:MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.